Why a single chart is not evidence
Online calculators often assume the stated vial amount is accurate and the material behaves like another formulation. Those assumptions are not established by a generic product page.
A concentration calculation can describe arithmetic, but it cannot validate identity, sterility, excipients, compatibility, or stability. This page therefore does not convert a research-vendor vial into administration instructions.
What a defensible record includes
- A lot-specific certificate of analysis with identity and assay information.
- A product-specific specification that identifies the formulation and fill amount.
- Stability and handling evidence for that exact formulation.
- A documented laboratory protocol appropriate to the approved research setting.
What this evidence review covers
Explain why ambiguous TB-500 identity prevents a universal preparation chart.
- Verify fragment versus full-length identity
- Required product documentation
- Mass versus concentration
- No generic calculator
- No extrapolation from Tβ4 trials
Source-backed findings
Each claim below is tied to the evidence class that can support it. Commercial listing data and clinical evidence remain separate.
entity
The FDA entity record distinguishes the TB-500 fragment from full-length Tβ4.
entity/route mismatch
Full-length clinical studies do not validate a vendor fragment preparation.
| Evidence class | What the source supports |
|---|---|
| entity | The FDA entity record distinguishes the TB-500 fragment from full-length Tβ4. |
| entity/route mismatch | Full-length clinical studies do not validate a vendor fragment preparation. |
Source-by-source evidence notes
These notes state what each inspected source can support and the boundary that should not be crossed when interpreting it.
FDA bulk substances that may present significant safety risks
Evidence class: primary regulatory. What it supports: FDA's BPC-157, injectable GHK-Cu, and TB-500 fragment safety/characterization statements; no identified human TB-500 fragment exposure data.
What it does not establish: A diagnosis, individual risk estimate, or claim that topical GHK-Cu and injectable GHK-Cu share one risk profile.
Intravenous full-length thymosin beta-4 in healthy volunteers
Evidence class: primary randomized phase 1 entity mismatch. What it supports: Short-term tolerability and pharmacokinetics of characterized full-length thymosin beta-4 in healthy volunteers.
What it does not establish: TB-500 fragment identity, TB-500 safety, injury healing, retail-product quality, or a TB-500 dose.
Full-length thymosin beta-4 ophthalmic solution phase 2 trial
Evidence class: primary randomized phase 2 entity and route mismatch. What it supports: 72-person ophthalmic full-length Tβ4 study; primary endpoints were not significant; selected secondary endpoints differed.
What it does not establish: TB-500 fragment efficacy, systemic administration, injury protocols, or retail-vial safety.
Questions this page answers
How much water goes into 5mg TB-500?
Do not answer generically; the label may not even resolve the entity, and stability/sterility are unverified.
Does mixing math prove concentration?
No. It assumes the labeled mass and identity are correct.
What remains unresolved
- Entity ambiguity across listings.
- No validated product instructions.
- No stability or sterility file.